Shengnuo Biotech announced that Factor Company Shengnuo Pharmaceuticals was included in the import ban list by the US FDA. The company and subsidiary signed a “return and refund agreement” with US customer A to return some of the peptide APIs. The company refunded the total amount of 249.596 million US dollars in installments. The company's revenue for the first three quarters of 2026 was 741 million yuan and net profit to mother was 171 million yuan; this refund is expected to reduce the current year's main business revenue by $163 million, total profit of 99.1137 million yuan, and net profit to mother by 84.2466 million yuan, without accounting data adjustments for the first three quarters of 2026 and the previous year.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.